|
AU2007205777A1
|
|
Use of HMGB fragments as anti-inflammatory agents
|
|
CA2659512A1
|
|
Novel piperazines, pharmaceutical compositions and methods of use thereof
|
|
EP2001861A2
|
|
New crystal forms and pharmaceutical compositions of (+)-r-zileuton
|
|
WO2007024840A2
|
|
Method of quantitating nucleic acids by flow cytometry microparticle-based array
|
|
EP1909834A2
|
|
Use of hmgb1 antagonists for the treatment of inflammatory skin conditions
|
|
WO2006012414A2
|
|
Novel polyadenylation signal for use in expression vectors
|
|
WO2006012373A2
|
|
Combination therapies of hmgb and complement inhibitors against inflammation
|
|
CN1878793A
|
|
Monoclonal antibodies against HMGB1
|
|
US2004156851A1
|
|
HMGB1 combination therapies
|
|
EP1569684A2
|
|
Use of hmgb fragments as anti-inflammatory agents
|
|
US2004141948A1
|
|
Use of HMGB fragments as anti-inflammatory agents
|
|
AU2003228593A1
|
|
Pharmaceutical composition comprising an alpha-ketoalkanoic acid ester or -amine and lactic acid or a lactic acid salt
|
|
AU2002254525B2
|
|
Method for preventing acute renal failure
|
